Copenhagen/London, August 2026 — Novo Nordisk and Amazon Web Services (AWS) have entered into a strategic partnership aimed at accelerating drug discovery and modernising Novo Nordisk’s operations through artificial intelligence and cloud technologies. Under the agreement, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner, bringing together Novo Nordisk’s pharmaceutical expertise with AWS’s scalable cloud infrastructure and AI capabilities.
Key Highlights
- AWS becomes Novo Nordisk’s preferred cloud provider and strategic AI partner for drug discovery and broader technology transformation.
- The companies have established an AI co-innovation hub in London, bringing together Novo Nordisk scientists, R&D teams, AWS engineers, AI specialists and applied scientists.
- Novo Nordisk plans to leverage Amazon Bio Discovery, Amazon Bedrock and Amazon Bedrock AgentCore to support target identification, therapeutic design, data analysis and AI-agent applications.
- The collaboration builds on existing AI deployments at Novo Nordisk, including a generative-AI solution used by more than 25,000 employees for productivity and information-management applications.
AI Moves Closer to the Core of Drug Discovery
The partnership represents a shift from using AI for individual research experiments toward embedding AI and cloud infrastructure across the drug-development value chain.
At the London co-innovation hub, Novo Nordisk’s R&D teams will work directly with AWS technical specialists to shorten the path from drug-target identification to first human dose. The model is designed to reduce handoffs between scientists, computational researchers and engineers, allowing AI-generated insights to move more rapidly into experimental validation.
AWS says its Amazon Bio Discovery service can provide scientists with access to biological AI models for generating and evaluating potential drug candidates, while integrated laboratory capabilities can help connect computational predictions with physical experimentation.
From Biological Data to AI-Enabled Drug Design
A major opportunity for the partnership is the ability to connect different types of pharmaceutical data—including genomic, imaging and clinical information—and use AI to generate insights that can influence both early research and clinical-development decisions.
Novo Nordisk will also use Amazon Bedrock AgentCore to develop AI-agent applications capable of working across enterprise data and performing multi-step workflows. This could allow AI to move from isolated analytical tasks toward more integrated research and operational processes.
Strategic Significance for Novo Nordisk
For Novo Nordisk, the partnership provides a technology foundation to scale AI across its global organisation while maintaining its core scientific and therapeutic expertise.
The company has already reported measurable benefits from its AWS relationship, including reduced clinical-documentation time and generative-AI applications being used by more than 25,000 employees. The expanded agreement now places greater emphasis on drug discovery and R&D, rather than AI being limited to productivity applications.
Industry Impact
The Novo Nordisk–AWS agreement illustrates a broader transformation in biopharma: hyperscalers are becoming strategic R&D partners rather than simply infrastructure providers.
The competitive model is increasingly becoming:
Pharma scientific expertise + proprietary biological data + AI foundation models + scalable cloud infrastructure + automated experimentation
This could enable pharmaceutical companies to move from isolated AI pilots toward AI-native drug discovery organisations, potentially compressing discovery timelines and increasing the number of biological hypotheses that can be tested.
BioNexAI Market Insights — Strategic Takeaway
The Novo Nordisk–AWS partnership is significant because it combines AI, cloud computing and pharmaceutical R&D under a single strategic framework. Rather than acquiring an AI biotech, Novo Nordisk is building an AI-enabled discovery infrastructure with a hyperscale technology partner. The London co-innovation hub could become a model for how large pharmaceutical companies integrate AI scientists, drug researchers and cloud engineers into a unified drug-discovery workflow.
By
